Luigi Grasso

This inventor holds 72 USPTO granted patents and 11 published patent applications, plus 16 CIPO patents and 20 EPO patents, primarily in Antibody Engineering (CPC class C07K). Top assignees: Morphotek, Inc., Johns Hopkins University, Genaera Corporation. Active years: 2003-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Luigi Grasso. Retrieved from https://idiyas.com/inventor/luigi-grasso

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 72 (Patent Applications = 11)

% Patents Active = 80.6

CIPO Patents = 16 (Patent Applications = 5)

EPO Patents = 20 (Patent Applications = 21)

Average Co-Inventor Count = 4.1

ph-index = 8

Forward Citations = 278(Granted Patents)

Forward Citations (Not Self Cited) = 188(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Philadelphia, PA (US) (2003 - 2012)
Bala Cynwyd, PA (US) (2007 - 2019)
Bryn Mawr, PA (US) (2010 - 2021)

Company Filing History:

Johns Hopkins University

Eisai R&d Management Co., Ltd.

7. 3 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2003-2026

Loading Chart...

Areas of Expertise:

Humoral Immune Suppressor

Antibody Dynamics

Monoclonal Antibodies

Tumor Antigens

Neutralizing Antibodies

Effector Activity

GM-CSF Peptides

Endosialin Binding

Anti-GD2 Antibodies

Hybridoma Production

Antimicrobial Agents

Mismatch Repair Inhibitors

72 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12516096 - Composition and Use of Humoral Immune Suppressor Antagonists for the Treatment of Humoral Immune Suppressed Diseases (2026-01-06),

2. 12416642 - Composition and methods for measuring antibody dynamics (2025-09-16),

3. 11129904 - Cys80 conjugated immunoglobulins (2021-09-28),

4. 10509037 - Monoclonal antibodies that specifically block biological activity of a tumor antigen (2019-12-17),

5. 10364284 - High affinity antibodies that neutralizeenterotoxin B (2019-07-30),

6. 10273310 - CYS80 conjugated immunoglobulins (2019-04-30),

7. 10253106 - Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells (2019-04-09),

8. 10053509 - Methods for inhibiting the binding of endosialin to ligands (2018-08-21),

9. 10023632 - Antigenic GM-CSF peptides and antibodies to GM-CSF (2018-07-17),

10. 9868780 - [object Object] (2018-01-16),

11. 9809647 - Neutralizing anti-CCL20 antibodies (2017-11-07),

12. 9650440 - Monoclonal antibodies that specifically block biological activity of a tumor antigen (2017-05-16),

13. 9624297 - Monoclonal antibodies that specifically block biological activity of a tumor antigen (2017-04-18),

14. 9522195 - Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells (2016-12-20),

15. 9505842 - Methods for inhibiting the binding of endosialin to ligands (2016-11-29),

Title: The Innovator Profile: Luigi Grasso

Introduction

Luigi Grasso, a prolific inventor based in Bryn Mawr, PA, is recognized for his significant contributions to the field of biotechnology with an impressive portfolio of 70 patents. His groundbreaking work has led to the development of novel immunoglobulins and monoclonal antibodies that hold promise in the treatment of various cancers.

Latest Patents

Among his latest patents is the innovative method for generating conjugated immunoglobulins by decapping a cysteine at amino acid position 80 ('Cys80') in a light chain variable region of an immunoglobulin and conjugating a thiol-reactive compound to the Cys80. Additionally, Grasso's invention of monoclonal antibodies that specifically block the biological activity of a tumor antigen, particularly the alpha-folate receptor, showcases his ingenuity in targeting cancer cells with precision.

Career Highlights

Having worked at esteemed institutions such as Morphotek, Inc. and The Johns Hopkins University, Luigi Grasso has honed his skills and expertise in the biotechnology sector. His relentless pursuit of innovation and dedication to advancing cancer treatment have earned him recognition among his peers and in the industry.

Collaborations

Throughout his career, Luigi Grasso has collaborated with notable professionals in the field, including coworkers Nicholas C Nicolaides and Philip M Sass. Together, they have brought forth cutting-edge research and developments that have the potential to transform the landscape of cancer therapeutics.

Conclusion

In conclusion, Luigi Grasso stands out as a visionary inventor whose relentless pursuit of innovation has led to groundbreaking advancements in biotechnology, particularly in the development of immunoglobulins and monoclonal antibodies for cancer treatment. His contributions continue to inspire progress in the field, offering hope for improved therapies and outcomes for patients worldwide.

Profile summary based on public USPTO records.